Suresh Alaparthy

9.4k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

Suresh Alaparthy is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Suresh Alaparthy has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Suresh Alaparthy's work include Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Immunotherapy and Immune Responses (5 papers). Suresh Alaparthy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Immunotherapy and Immune Responses (5 papers). Suresh Alaparthy collaborates with scholars based in United States, India and Canada. Suresh Alaparthy's co-authors include Scott D. Chasalow, Omid Hamid, Vafa Shahabi, Henrik Schmidt, Jeffrey R. Jackson, David M. Berman, Rui‐Ru Ji, John Cogswell, Nathan O. Siemers and Lisu Wang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Diabetes.

In The Last Decade

Suresh Alaparthy

21 papers receiving 1.2k citations

Hit Papers

An immune-active tumor microenvironment favors clinical r... 2011 2026 2016 2021 2011 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An immune-active tumor microenvironment favors clinical response to ipilimumab
    2011 593 citations Rui‐Ru Ji, Scott D. Chasalow et al. Cancer Immunology Immunotherapy profile →

Peers

Suresh Alaparthy
Heather Metz United States
Elizabeth Liniker Australia
Hiroshi Yamaguchi Japan
Jing-Jing Zhao China
Anne Montfort France
M. Thomas France
Michael Chisamore United States
Qiu-Zhong Pan China
Heather Metz United States
Suresh Alaparthy
Citations per year, relative to Suresh Alaparthy Suresh Alaparthy (= 1×) peers Heather Metz

Countries citing papers authored by Suresh Alaparthy

Since Specialization
Citations

This map shows the geographic impact of Suresh Alaparthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suresh Alaparthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suresh Alaparthy more than expected).

Fields of papers citing papers by Suresh Alaparthy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suresh Alaparthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suresh Alaparthy. The network helps show where Suresh Alaparthy may publish in the future.

Co-authorship network of co-authors of Suresh Alaparthy

This figure shows the co-authorship network connecting the top 25 collaborators of Suresh Alaparthy. A scholar is included among the top collaborators of Suresh Alaparthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suresh Alaparthy. Suresh Alaparthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rizvi, Naiyer A., Laura Q.M. Chow, Hossein Borghaei, et al.. (2014). Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.. Journal of Clinical Oncology. 32(15_suppl). 8022–8022. 99 indexed citations
2.
Gettinger, Scott, Frances A. Shepherd, Scott Antonia, et al.. (2014). First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.. Journal of Clinical Oncology. 32(15_suppl). 8024–8024. 87 indexed citations
3.
Antonia, Scott, Julie R. Brahmer, Scott Gettinger, et al.. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 32(15_suppl). 8113–8113. 72 indexed citations
4.
Weber, Jeffrey S., Omid Hamid, Asim Amin, et al.. (2013). Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.. PubMed Central. 58 indexed citations
5.
Rizvi, Naiyer A., Scott Antonia, Laura Q.M. Chow, et al.. (2013). A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology. 31(15_suppl). 8072–8072. 39 indexed citations
6.
Shahabi, Vafa, Gena S. Whitney, Omid Hamid, et al.. (2012). Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunology Immunotherapy. 61(5). 733–737. 63 indexed citations
7.
Ji, Rui‐Ru, Scott D. Chasalow, Lisu Wang, et al.. (2011). An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology Immunotherapy. 61(7). 1019–1031. 593 indexed citations breakdown →
8.
Jackson, Jennifer, Gena S. Whitney, Omid Hamid, et al.. (2011). Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab.. Journal of Clinical Oncology. 29(15_suppl). 2587–2587. 5 indexed citations
9.
Ji, Rui‐Ru, Omid Hamid, Scott D. Chasalow, et al.. (2011). Abstract 5513: An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Research. 71(8_Supplement). 5513–5513. 5 indexed citations
10.
Hamid, Omid, Scott D. Chasalow, Zenta Tsuchihashi, et al.. (2009). Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. Journal of Clinical Oncology. 27(15_suppl). 9008–9008. 32 indexed citations
11.
Parker, Susan, David M. Berman, Kelly L. Bennett, et al.. (2009). Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab. Journal of Clinical Oncology. 27(15_suppl). 3031–3031. 1 indexed citations
12.
Berman, David M., Susan Parker, Scott D. Chasalow, et al.. (2008). Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. Journal of Clinical Oncology. 26(15_suppl). 3022–3022. 9 indexed citations
13.
Alaparthy, Suresh, Liliana Guédez, Jan S. Moreb, & James R. Zucali. (2003). Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. British Journal of Haematology. 120(3). 457–463. 29 indexed citations
14.
Guédez, Liliana, et al.. (1996). Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl‐2. European Journal Of Haematology. 57(2). 149–156. 11 indexed citations
15.
Goldschmidt, Raúl, MaryBeth Frosco, Suresh Alaparthy, & John F. Barrett. (1996). Meeting Highlights Anti-infectives: 96th General Meeting of the American Society for Microbiology New Orleans, Louisiana, USA, 19–23 May, 1996. Expert Opinion on Investigational Drugs. 5(7). 887–896. 1 indexed citations
16.
Sodhi, Ajit, Suresh Alaparthy, & Sukh Mahendra Singh. (1993). Effect of interferon-gamma, tumor necrosis factor, interleukin-1 and interleukin-6 on the modulation of anti-tumor responses of bone marrow derived macrophages. International Journal of Immunopharmacology. 15(3). 327–334. 6 indexed citations
17.
Alaparthy, Suresh, Ajit Sodhi, Sukh Mahendra Singh, & Sunanda Basu. (1991). In vitro activation of murine bone marrow-derived macrophages with cisplatin and mitomycin-C. International Journal of Immunopharmacology. 13(2-3). 189–195. 16 indexed citations
18.
Sodhi, Ajit, Suresh Alaparthy, & Sukh Mahendra Singh. (1991). In vitro activation of rGM‐CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide. Immunology and Cell Biology. 69(4). 235–241. 9 indexed citations
19.
Basu, Sunanda, Ajit Sodhi, Sukh Mahendra Singh, & Suresh Alaparthy. (1991). Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin. Immunology Letters. 27(3). 199–204. 16 indexed citations
20.
Alaparthy, Suresh & Ajit Sodhi. (1991). Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharide. Immunology Letters. 30(1). 93–100. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heather Metz Breakdown of academic impact, for papers by Elizabeth Liniker Breakdown of academic impact, for papers by Hiroshi Yamaguchi Breakdown of academic impact, for papers by Jing-Jing Zhao Breakdown of academic impact, for papers by Anne Montfort Breakdown of academic impact, for papers by M. Thomas Breakdown of academic impact, for papers by Michael Chisamore Breakdown of academic impact, for papers by Qiu-Zhong Pan
Rankless by CCL
2026